NUVECTIS PHARMA INC's ticker is and the CUSIP is 67080T108. A total of 1 filers reported holding NUVECTIS PHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $1,184,614 | -21.0% | 142,040 | +22.0% | 0.09% | -27.9% |
| Q3 2023 | $1,500,138 | +4.3% | 116,380 | +29.2% | 0.13% | +9.3% |
| Q2 2023 | $1,438,274 | -23.7% | 90,061 | -37.4% | 0.12% | -28.0% |
| Q1 2023 | $1,885,218 | +88.6% | 143,800 | +7.9% | 0.16% | +80.2% |
| Q4 2022 | $999,750 | +6.0% | 133,300 | +0.2% | 0.09% | -30.0% |
| Q3 2022 | $943,000 | -30.4% | 133,000 | +9.9% | 0.13% | -26.1% |
| Q2 2022 | $1,355,000 | – | 121,000 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BALDWIN BROTHERS LLC/MA | 116,380 | $1,500,138 | 0.13% |
| FORBES J M & CO LLP | 34,000 | $438,260 | 0.06% |
| Moran Wealth Management, LLC | 16,697 | $215,224 | 0.01% |
| Dorsey Wright & Associates | 1,396 | $17,994 | 0.01% |
| Tower Research Capital LLC (TRC) | 7,282 | $93,865 | 0.00% |
| MARSHALL WACE, LLP | 36,085 | $465,136 | 0.00% |
| Renaissance Technologies | 25,400 | $327 | 0.00% |
| UBS Group AG | 3,776 | $48,672 | 0.00% |
| RHUMBLINE ADVISERS | 7,273 | $93,742 | 0.00% |
| HOLLENCREST CAPITAL MANAGEMENT | 280 | $3,609 | 0.00% |